Overview
- Yahoo Finance reports an average analyst price target of $93.39 for Viking Therapeutics, implying roughly 175% upside from recent levels.
- VK2735, a GLP-1 candidate for weight management, is in a 78-week subcutaneous phase 3 trial that completed enrollment in late 2025, with full results expected in 2027.
- An interim look at the phase 3 study in 2026 is described as possible but not assured.
- Viking is running a phase 1 maintenance study assessing daily and weekly oral regimens and a monthly injection in patients who previously lost weight on VK2735.
- Analysts expect limited near-term stock impact from the phase 1 readout given its safety focus, after a year marked by a poorly received data release and underperformance versus the S&P 500.